New drugs for tuberculosis treatment

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 29, Issue SUPPL. 1, 2011, Pages 47-56

  Sánchez, Francesca ^a,b   López Colomés, José L ^a,b   Villarino, Elsa ^b   Grosset, Jacques ^b,c  

^a HOSPITAL DEL MAR   (Spain)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

High dose of rifamycins; New drug combinations

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; LINEZOLID; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADD ON THERAPY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BONE MARROW SUPPRESSION; BRUCELLOSIS; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INHIBITION; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FLU LIKE SYNDROME; HEPATITIS; HUMAN; INSOMNIA; LATENT TUBERCULOSIS; LIVER TOXICITY; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYALGIA; NAUSEA; NEUROPATHY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PLASMA PROTEIN BINDING; QT PROLONGATION; SINGLE DRUG DOSE; SKIN LEISHMANIASIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREMOR; TUBERCULOSIS; TUBERCULOSIS CONTROL; VOMITING;

ANIMALS; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FORECASTING; GUINEA PIGS; HUMANS; MICE; PRIMATES; RABBITS; RIFAMPIN; TUBERCULOSIS;

EID: 79952958570     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(11)70018-0     Document Type: Article

References (105)

1. T. Barr, G. Tubach, Cliff Notes: On Steinbeck's Of Mice and men 2001 Third Avenue New York City 909
2. W.J. Burman, K. Gallicano, and C. Peloquin Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials Clin Pharmacokinet 40 2001 327 341 (Pubitemid 32565595)
3. A.H. Diacon, R.F. Patientia, A. Venter, P.D. Van Helden, P.J. Smith, and H. McIlleron Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears Antimicrob Agents Chemother 51 2007 2994 2996 (Pubitemid 47206244)
4. S.H. Gillespie Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective Antimicrob Agents Chemother 46 2002 267 274 (Pubitemid 34087167)
5. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. 2002-2007. Geneva: World Health Organization; 2008.
6. G. Acocella Clinical pharmacokinetics of rifampicin Clin Pharmacokinet 3 1978 108 127
7. R. Ruslami, H.M.J. Nijland, B. Alisjahbana, I. Parwati, R. Van Crevel, and R.E. Aarnoutse Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients Antimicrob Agents Chemother 51 2007 2546 2551 (Pubitemid 47047335)
8. M. Niemi, J.T. Backman, M.F. Fromm, P.J. Neuvonen, and K.T. Kivisto Pharmacokinetic interactions with rifampicin: clinical relevance Clin. Pharmacokinet 42 2003 819 850 (Pubitemid 36995083)
9. L.B. Heifets, P.J. Lindholm-Levy, and M.A. Flory Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis Am Rev Respir Dis 141 1990 626 630 (Pubitemid 20109150)
10. V. Jayashree, S. Nandi, R. Bharat, K. Shandil, E. Kantharaj, and V. Balasubramanian Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis Antimicrob Agents Chemother 47 2003 2118 2124 (Pubitemid 36753560)
11. B. Kreis, S. Pretet, J. Birenbaum, P. Guibout, J.J. Hazeman, and E. Orin Two three-month treatment regimens for pulmonary tuberculosis Bull Int Union Tuberc 51 1976 71 75
12. M.W. Long, D.E. Snider Jr, and L.S. Farer US Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis Am Rev Respir Dis 119 1978 879 894
13. D.K. Kochar, S. Aseri, B.V. Sharma, R.A. Bumb, R.D. Mehta, and S.K. Purohit The role of rifampicin in the management of cutaneous leishmaniasis QJM 93 2000 733 737
14. J.M. Solera, P. Rodríguez-Zapata, J. Geijo, J. Largo, L. Paulino, E. Sáez The GECMEI Group Doxycycline-rifampin versus doxycycline- streptomycin in treatment of human brucellosis due to Brucella melitensis Antimicrob Agents Chemother 39 1995 2061 2067
15. M. Kissling, and N. Bergamini Rifampicin in free combination with other antimicrobial drugs in non-Tb infections. Clinical data on 650 patients (a review) Chemotherapy 27 1981 368 402 (Pubitemid 11072102)
16. D.L. Williams, L. Spring, L. Collins, L.P. Miller, L.B. Heifets, and P.R.J. Gangadharam Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis Antimicrob Agents Chemother 42 1998 1853 1857 (Pubitemid 28311593)
17. N. Mor, B. Simon, N. Mezo, and L. Heifets Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages Antimicrob Agents Chemother 39 1995 2073 2077
18. M. Weiner, N. Bock, C.A. Peloquin, W.J. Burman, A. Khan, and A. Vernon Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy Am J Respir Crit Care Med 169 2004 1191 1197 (Pubitemid 38680395)
19. K. Dooley, C. Flexner, J. Hackman, C.A. Peloquin, E. Nuermberger, and R.E. Chaisson Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations Antimicrob Agents Chemother 52 2008 4037 4042
20. P. Bemer-Melchior, A. Bryskier, and H.B. Drugeon Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex J Antimicrob Chemother 46 2000 571 576
21. E. Nuermberger, and J. Grosset Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections Eur J Clin Microbiol Infect Dis 23 2004 243 255 (Pubitemid 38669936)
22. A. Vernon, W. Burman, D. Benator, A. Khan, and L. Bozeman Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid Lancet 353 1999 1843 1847 (Pubitemid 29251017)
23. D. Benator, M. Bhattacharya, L. Bozeman, W. Burman, A. Cantazaro, and R. Chaisson Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Lancet 360 2002 528 534
24. B. Jarvis, and H.M. Lamb Rifapentine Drugs 56 1998 607 616 (Pubitemid 28488266)
25. I.M. Rosenthal, K. Williams, S. Tyagi, C. Peloquin, A. Vernon, and W.R. Bishai Potent twice-weekly rifapentine-containing regimens in murine tuberculosis Am J Respir Crit Care Med 174 2006 94 101 (Pubitemid 43955249)
26. I.M. Rosenthal, Williams, S. Tyagi, A. Vernon, C.A. Peloquin, and W.R. Bishai Weekly moxifloxacin and rifapentine is more active than the Denver regimen in murine tuberculosis Am J Respir Crit Care Med 172 2005 1457 1462 (Pubitemid 43069821)
27. I.M. Rosenthal, M. Zhang, K.N. Williams, C.A. Peloquin, S. Tyagi, and A. Vernon Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model PLoS Med 4 2007 e344
28. E. Nuermberger, I.M. Rosenthal, M. Zhang, and J. Grosset Relative contribution of moxifloxacin versus isoniazid to rifapentine-based regimens in the murine model of tuberculosis. 1st Int Workshop Clin Pharmacol Tuberculosis Drugs Toronto 2008 18 Abstract
29. I.M. Rosenthal, M. Zhang, J. Grosset, and E. Nuermberger Is it possible to cure TB in weeks instead of months? 1st Int Workshop Clin Pharmacol Tuberculosis Drugs Toronto 2008 19 Abstract
30. N. Bock, T.R. Sterling, C.D. Hamilton, C. Pachucki, Y.C. Wang, and D.S. Conwell A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment Am J Respir Crit Care Med 165 2002 1526 1530 (Pubitemid 34606668)
31. M. Weiner, N. Bock, C.A. Peloquin, W.A. Burman, A. Khan, and A. Vernon Pharmacokinetics rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy Am J Respir Crit Care Med 169 2004 1191 1197 (Pubitemid 38680395)
32. E. Nuermberger, S. Tyagi, K.N. Williams, I. Rosenthal, W.R. Bishai, and J.H. Grosset Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model Am J Respir Crit Care Med 172 2005 1452 1456 (Pubitemid 43069820)
33. M. Schechter, R. Zajdenverg, G. Falco, G.L. Barnes, J.C. Faulhaber, and J.S. Coberly Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts Am J Respir Crit Care Med 173 2006 922 926
34. World Health Organization Treatment of tuberculosis. Guidelines for national programmes 3rd ed. 2003 World Health Organization Geneva
35. D.P. Bonner In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin J Antimicrob Chemother 45 2000 437 446
36. R.K. Shandil, R. Jayaram, P. Kaur, S. Gaonkar, B.L. Suresh, and B.N. Mahesh Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy Antimicrob Agents Chemother 51 2007 576 582 (Pubitemid 46185275)
37. H. Stass, A. Dalhoff, D. Kubitza, and U. Schuhly Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects Antimicrob Agents Chemother 42 1998 2060 2065 (Pubitemid 28363093)
38. A.V. Shindikar, and C.L. Viswanathan Novel fluoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv Bioorg Med Chem Lett 15 1998 1803 1806
39. L. Bozeman, W. Burman, B. Metchock, L. Welch, and M. Weiner Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada Clin Infect Dis 40 2005 386 391 (Pubitemid 40216506)
40. A.S. Ginsburg, S.C. Woolwine, N. Hooper, W.H. Benjamin Jr, W.R. Bishai, and S.E. Dorman The rapid development of fluoroquinolone resistance in M. tuberculosis N. Engl J Med 349 2003 1977 1978 (Pubitemid 37409723)
41. A.S. Ginsburg, J.H. Grosset, and W.R. Bishai Fluoroquinolones, tuberculosis, and resistance Lancet Infect Dis 3 2003 432 442 (Pubitemid 36791119)
42. K.M. Kam, C.W. Yip, T.L. Cheung, H.S. Tang, C.C. Leung, and M.Y. Chan Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility Microb Drug Resist 12 2006 7 11
43. A.M. Ginsberg, and M. Spigelman Challenges in tuberculosis drug research and development Nat Med 13 2007 290 294 (Pubitemid 46376672)
44. T.S. Huang, C. Kunin, L.S. Shin-Jung, Y.S. Chen, H.Z. Tu, and Y.C. Liu Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003 J Antimicrob Chemother 56 2005 1058 1062 (Pubitemid 43009820)
45. H.M. Nijland, R. Ruslami, A.J. Suroto, D.M. Burger, B. Alisjahbana, and R. Van Crevel Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis Clin Infect Dis 45 2007 1001 1007 (Pubitemid 47580349)
46. M. Weiner, W. Burman, C.C. Leung, C.A. Peloquin, M. Engle, and S. Goldberg Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin Antimicrob Agents Chemother 51 2007 2861 2866 (Pubitemid 47206223)
47. D.H. Wright, G.H. Brown, M.L. Peterson, and J.C. Rotschafer Application of fluoroquinolone pharmacodynamics J Antimicrob Chemother 46 2000 669 683
48. T. Yoshimatsu, E. Nuermberger, S. Tyagi, R. Chaisson, W. Bishai, and J. Grosset Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis Antimicrob Agents Chemother 46 2002 1875 1879 (Pubitemid 34535210)
49. N. Lounis, A. Bentoucha, C. Truffot-Pernot, B. Ji, R.J. O'Brien, and A. Vernon Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice Antimicrob Agents Chemother 45 2001 3482 3486 (Pubitemid 33107866)
50. E.L. Nuermberger, T. Yoshimatsu, S. Tyagi, R.J. O'Brien, A. Vernon, and R.E. Chaisson Moxifloxacin containing regimen greatly reduces time to culture conversion in murine tuberculosis Am J Respir Crit Care Med 169 2004 421 426 (Pubitemid 38134824)
51. M.W.R. Pletz, A. De Roux, A. Roth, K.H. Neumann, H. Mauch, and H. Lode Early bactericidal activty of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study Antimicrob Agents Chemother 48 2004 780 782 (Pubitemid 38280324)
52. S.H. Gillespie, R.D. Gosling, L. Uiso, N.E. Sam, E.G. Kanduma, and T.D. McHugh Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis J Antimicrob Chemother 56 2005 1169 1171 (Pubitemid 43009844)
53. W.J. Burman, S. Goldberg, J.L. Johnson, G. Muzanye, M. Engle, and A.W. Mosher Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis Am J Respir Crit Care Med 174 2006 331 338 (Pubitemid 44156613)
54. R. Rustomjee, C. Lienhardt, T. Kanyok, G.R. Davies, J. Levin, and T. Mthiyane A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis Int J Tuberc Lung Dis 12 2008 128 138 (Pubitemid 351212403)
55. N. Veziris, N. Lounis, A. Chauffour, C. Truffot-Pernot, and V. Jarlier Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice Antimicrob Agents Chemother 49 2005 4015 4019 (Pubitemid 41400940)
56. L.R. Codecasa, G. Ferrara, M. Ferrarese, M.A. Morandi, V. Penati, and C. Lacchini Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs Respir Med 100 2006 1566 1572 (Pubitemid 44109116)
57. European Medicines Agency Questions and answers on the recommendation to restrict the use of oral formulations of moxifloxacin-containing medicines 2008 European Medicines Agency London
58. A. Lubasch, I. Keller, K. Borner, P. Koeppe, and H. Lode Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers Antimicrob Agents Chemother 44 2000 2600 2603
59. L.Y. Park-Wyllie, D.N. Juurlink, A. Kopp, B.R. Shah, T.A. Stukel, and C. Stumpo Outpatient gatifloxacin therapy and dysglycemia in older adults N Engl J Med 354 2006 1352 1361
60. T. Lu, and K. Drlica In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents J Antimicrob Chemother 52 2003 1025 1028 (Pubitemid 38008428)
61. M.H. Cynamon, and M. Sklaney Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis Antimicrob Agents Chemother 47 2002 2442 2444
62. K. Yanagihara, Y. Kaneko, T. Sawai, Y. Miyazaki, K. Tsukamoto, and Y. Hirakata Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection Antimicrob Agents Chemother 46 2002 3288 3291
63. L. Alcalá, M.J. Ruiz-Serrano, and C. Pérez-Fernández Turégano In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs Antimicrob Agents Chemother 47 2003 416 417 (Pubitemid 36070399)
64. R.J. Wallace Jr, B.A. Brown-Elliott, and S.C. Ward Activities of linezolid against rapidly growing mycobacteria Antimicrob Agents Chemother 45 2001 764 767 (Pubitemid 32182022)
65. M.H. Cynamon, S.P. Klemens, and C.A. Sharpe Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model Antimicrob Agents Chemother 43 1999 1189 1191 (Pubitemid 29214745)
66. M.E. Valencia, V. Moreno, and F. Laguna Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection. Are there new therapeutic possibilities? Enferm Infecc Microbiol Clin 19 2001 37 39 (Pubitemid 32199258)
67. B.A. Brown-Elliott, R.J. Wallace Jr, R. Blinkhorn, C.J. Crist, and L.B. Mann Successful treatment of disseminated Mycobacterium chelonae infection with linezolid Clin Infect Dis 33 2001 1433 1434 (Pubitemid 32955202)
68. G.B. Migliori, B. Eker, M.D. Richardson, G. Sotgiu, J.P. Zellweger, A. Skrahina TBNET Study Group A retrospective TBNET assessment of linezolid, safety, tolerability and efficacy in multidrug resistant tuberculosis Eur Respir J 34 2009 387 393
69. E. Rubinstein, R. Isturiz, and H.C. Standiford Worldwide assessment of linezolid's clinical safety and tolerability:comparator controlled phase III studies Antimicrob Agents Chemother 47 2003 1824 1831 (Pubitemid 36637801)
70. S.L. Gerson, S.L. Kaplan, and J.B. Bruss Hematologic effects of linezolid:summary of clinical experience Antimicrob Agents Chemother 46 2002 2723 2726 (Pubitemid 34793498)
71. A.M. Bressler, S.M. Zimmer, and J.L. Gilmore Peripheral neuropathy associated with prolonged use of linezolid Lancet Infect Dis 4 2004 528 531 (Pubitemid 39077924)
72. J. Fortún, P. Martín-Dávila, E. Navas, M.J. Pérez-Elías, J. Cobo, and M. Tato Linezolid for the treatment of multidrug resistant tuberculosis J Antimicrobl Chemother 56 2005 180 185
73. I.N. Park, S.B. Hong, Y.M. Oh, M.N. Kim, C.M. Lim, and S.D. Lee Efficacy and tolerability of daily half-dose of linezolid in patients with intractable multidrug resistant tuberculosis J Antimicrob Chemother 58 2006 701 704 (Pubitemid 44288145)
74. K. Andries, P. Verhasselt, J. Guillemont, H.W. Gohlmann, J.M. Neefs, and H. Winkler A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 307 2005 223 227 (Pubitemid 40116230)
75. M.R. De Jonge, L.H. Koymans, J.E. Guillemont, A. Koul, and K. Andries A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910 Proteins 67 2007 971 980 (Pubitemid 46753944)
76. A.H. Diacon, A. Pym, M. Grobusch, R. Patientia, R. Rustomjee, and L. Page-Shipp The diarylquinoline TMC207 for multidrug resitant tuberculosis N Eng J Med 360 2009 2397 2405
77. S. Petrella, E. Cambau, A. Chauffour, K. Andries, V. Jarlier, and W. Sougakoff Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria Antimicrob Agents Chemother 50 2006 2853 2856 (Pubitemid 44198713)
78. R. Rustomjee, A.H. Diacon, J. Allen, A. Venter, C. Reddy, and R.F. Patientia Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis Antimicrob Agents Chemother 52 2008 2831 2835
79. N. Lounis, T. Gevers, J. Van Den Berg, and K. Andries Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model Antimicrob. Agents Chemother 52 2008 3568 3572
80. E. Huitric, P. Verhasselt, K. Andries, and S.E. Hoffner In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor Antimicrob Agents Chemother 51 2007 4202 4204 (Pubitemid 350057830)
81. N. Veziris, M. Ibrahim, N. Lounis, A. Chauffour, C. Truffot-Pernot, and K. Andries A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis Am J Respir Crit Care Med 179 2009 75 79
82. M. Ibrahim, K. Andries, N. Lounis, A. Chauffour, C. Truffot-Pernot, and V. Jarlier Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis Antimicrob Agents Chemother 51 2007 1011 1015 (Pubitemid 46355288)
83. A.J. Lenaerts, D. Hoff, S. Aly, S. Ehlers, K. Andries, and L. Cantarero Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910 Antimicrob Agents Chemother 51 2007 3338 3345 (Pubitemid 350067549)
84. M.V. Papadopoulou, W.D. Bloomer, and M.R. McNeil NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis Int J Antimicrob Agents 29 2007 724 727 (Pubitemid 46722678)
85. M.K. Spigelman New tuberculosis therapeutics: a growing pipeline J Infect Dis 196 Suppl 1 2006 S28 S34
86. C.K. Stover, P. Warrener, D.R. Van Devanter, D.R. Sherman, T.M. Arain, and M.H. Langhorne A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis Nature 405 2000 962 966 (Pubitemid 30435054)
87. K.P. Choi, T.B. Bair, Y.M. Bae, and L. Daniels Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F420 biosynthesis by Mycobacterium bovis BCG J Bacteriol 183 2001 7058 7066 (Pubitemid 33121838)
88. U.H. Manjunatha, H. Boshoff, C.S. Dowd, L. Zhang, T.J. Albert, and J.E. Norton Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis Proc Natl Acad Sci USA 103 2006 431 436 (Pubitemid 43122418)
89. E. Nuermberger, I. Rosenthal, S. Tyagi, K.N. Williams, D. Almeida, and C.A. Peloquin Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis Antimicrob Agents Chemother 50 2006 2621 2625 (Pubitemid 44198679)
90. S. Tyagi, E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, and S. Lounis Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis Antimicrob Agents Chemother 49 2005 2289 2293 (Pubitemid 40734456)
91. A.J. Lenaerts, V. Gruppo, K.S. Marietta, C.M. Johnson, D.K. Driscoll, and N.M. Tompkins Mycobacterium tuberculosis in a series of in vitro and in vivo models Antimicrob Agents Chemother 49 2005 2294 2301
92. I. Rosenthal, and J.H. Grosset Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis Antimicrob Agents Chemother 52 2008 1522 1524 (Pubitemid 351522025)
93. R. Tasneen, S. Tyagi, K. Williams, J. Grosset, and E. Nuermberger Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis Antimicrob Agents Chemother 52 2008 3664 3668
94. H. Sasaki, Y. Haraguchi, M. Itotani, H. Kuroda, H. Hashizume, and T. Tomishige Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2-,3-dihydroimidazo[2,1-b]oxazoles J Med Chem 49 2006 7854 7860 (Pubitemid 46033674)
95. M. Matsumoto, H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, and H. Sasaki OPC-67683, a nitrodihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice PLoS Med 3 2006 e466
96. L. Jia, J.E. Tomaszewski, P.E. Noker, G.S. Gorman, E. Glaze, and M. Protopopova Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization J Pharm Biomed Anal 37 2005 793 799 (Pubitemid 40417755)
97. P. Chen, J. Gearhart, M. Protopopova, L. Einck, and C.A. Nacy Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro J Antimicrob Chemother 58 2006 332 337 (Pubitemid 44294944)
98. L. Jia, P.E. Noker, L. Coward, G.S. Gorman, M. Protopopova, and J.E. Tomaszewski Interspecies pharmacokinetics and in vitro metabolism of SQ109 Br J Pharmacol 147 2006 476 485 (Pubitemid 43355045)
99. Horwith G, Protopopova M, Lyer L, Mirsalis J, Li Y, Swezey R. Drug-drug interaction studies of SQ109 with first-line anti-TB drugs, abstr. 16. Abstr. 1st Int. Workshop Clin. Pharmacol. Tuberculosis Drugs. 2008; Toronto, Canada.
100. P. Chen, J. Gearhart, M. Protopopova, L. Einck, and C.A. Nacy Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro J Antimicrob Chemother 58 2006 332 337 (Pubitemid 44294944)
101. B.V. Nikonenko, M. Protopopova, R. Samala, L. Einck, and C.A. Nacy Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs Antimicrob Agents Chemother 51 2007 1563 1565 (Pubitemid 46586854)
102. S.K. Arrora, N. Sinha, R. Sinha, R. Bateja, S. Sharma, and R.S. Upadhayaya Design, synthesis, modelling and activity of novel antitubercular compounds Am Chem Soc Meet 2004 abstr. 63. Abstr
103. M. Protopopova, E. Bogatcheva, B. Nikonenko, S. Hundert, L. Einck, and C.A. Nacy In search of new cures for tuberculosis Med Chem 3 2007 301 316 (Pubitemid 46773948)
104. Tuberculosis. Ll-3858. Tuberculosis (Edinburgh). 2008; 88:126.
105. T. Cohen, and M. Murray Incident tuberculosis among recent US immigrants and exogenous reinfection Emerg Infect Dis 11 2005 725 728 (Pubitemid 40586400)